Hemospan: A hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia

Current Opinion in Investigational Drugs

Volumn 9, Issue 9, 2008, Pages 1009-1019

  Smani, Y ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; HEMOSPAN; POLYMERIZED HEMOGLOBIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; FLANK PAIN; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; LIMB ISCHEMIA; MEAN ARTERIAL PRESSURE; OXYGEN BLOOD LEVEL; PHASE 3 CLINICAL TRIAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD SUBSTITUTES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CRITICAL CARE; EXTREMITIES; HEMOGLOBINS; HUMANS; ISCHEMIA; OXYGEN CONSUMPTION; PATENTS AS TOPIC; REGIONAL BLOOD FLOW; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 50249150337     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. 309897 The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. Gould SA, Moore EE, Hoyt DB, Burch JM, Haenel JB, Garcia J, DeWoskin R, Moss GS J AM COLL SURG 1998 187 2 113-122
2. 392703 Future prospects for artificial blood. Chang TMS TRENDS BIOTECHNOL 1999 17 2 61-67
3. 504280 Sangart and Gambro enter into strategic partnership. Sangart Inc PRESS RELEASE 2001 July 27
4. 504292 MP4, a new non-vasoactive PEG-Hb conjugate. Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM TRANSFUSION 2003 43 4 509-516
5. 504294 Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Wettstein R, Tsai AG, Erni D, Winslow RM, Intaglietta M CRIT CARE MED 2003 31 6 1824-1830
6. 612991 Sangart starts US blood substitute phase II trial. Sangart Inc PRESS RELEASE 2005 July 19
7. 647478 Biopure launches Hemopure blood substitute in South Africa. Biopure Corp PRESS RELEASE 2006 January 30
8. 50 about 7 mmHg) lower the minimal permissive (critical) hematocrit in rats. Winslow RM, Lohman J, Malavalli A, Vandegriff KD BLOOD 2003 102 11 Pt 2 137b-138b
9. 2 therapeutics. Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM AM J PHYSIOL 2003 285 4 Pt 2 H1411-H1419
10. 738746 Resuscitation with the human hemoglobin-based oxygen carrier (MP4): Equivalence to autologous blood following hemorrhage in rats. Young M, Lohman J, Gottschalk L, Vandegriff K, Winslow R FASEB J 2003 17 5 Pt 2 A1239
11. 738751 MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Young MA, Riddez L, Kjellstrom BT, Bursell J, Winslow F, Lohman J, Winslow RM CRIT CARE MED 2005 33 8 1794-1804
12. 738752 A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Bjorkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM HAEMATOLOGICA 2005 90 4 505-515
13. 50 hemoglobin: A new basis for hemoglobin-based oxygen carriers. Winslow RM ARTIF CELS BLOD SUBST BIOTECHNOL 2005 33 1 1-12
14. 738756 Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). Drobin D, Kjellstrom BT, Malm E, Malavalli A, Lohman J, Vandegriff KD, Young MA, Winslow RM J APPL PHYSIOL 2004 96 5 1843-1853
15. 738757 Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. Winslow RM, Lohman J, Malavalli A, Vandegriff KD J APPL PHYSIOL 1985 97 4 1527-1534
16. 738758 MP4, a new nonvasoactive polyethylene glycol-hemoglobin conjugate. Winslow RM ARTIF ORGANS 2004 28 9 800-806
17. 2 binding to a maleimide poly(ethylene glycol)-conjugated human haemoglobin. Vandegriff KD, Bellelli A, Samaja M, Malavalli A, Brunori M, Winslow RM BIOCHEM J 2004 382 1 183-189
18. 752804 A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Olofsson C, Ahl T, Johansson T, Larsson S, Nellgard P, Ponzer S, Fagrell B, Przybelski R, Keipert P, Winslow N, Winslow RM ANESTHESIOLOGY 2006 105 6 1153-1163
19. 758747 HHS announces $175 million in grant opportunities for states to assist health care providers in the Gulf coast region. U.S. Department of Health and Human Services PRESS RELEASE 2007 January 18
20. 765752 Sangart starts European phase III Hemospan trials. Sangart Inc PRESS RELEASE 2007 February 13
21. 765944 NCT00420277: Phase III efficacy and safety study of Hemospan for treating hypotension in hip arthroplasty. CLINICALTRIALS.GOV 2007 January 18
22. 765946 NCT00421200: Phase III efficacy and safety study of Hemospan to prevent hypotension in hip arthroplasty. CLINICALTRIALS.GOV 2007 January 18
23. 824526 Biopure applies for compassionate use of Hemopure for anemia in US. Biopure Corp PRESS RELEASE 2007 August 23
24. 865552 Sangart begins phase II limb ischemia trial of Hemospan. Sangart Inc PRESS RELEASE 2008 January 07
25. 888572 Sangart completes enrollment in phase III study of its novel blood substitute Hemospan. Sangart Inc PRESS RELEASE 2008 March 24
26. 897006 A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Olofsson C, Nygards EB, Ponzer S, Fagrell B, Przybelski R, Keipert PE, Winslow N, Winslow RM TRANSFUS MED 2008 18 1 28-39
27. 897007 Effect of maleimide-polyethylene glycol hemoglobin (MP4) on hemodynamics and acid-base status after uncontrolled hemorrhage in anesthetized swine: Comparison with crystalloid and blood. Young MA, Riddez L, Kjellstrom BT, Winslow RM J TRAUMA 2007 63 6 1234-1244
28. 897010 Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: Implications for a new oxygen therapeutic. Svergun DI, Ekstrom F, Vandegriff KD, Malavalli A, Baker DA, Nilsson C, Winslow RM BIOPHYS J 2008 94 1 173-181
29. 897014 Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Young MA, Malavalli A, Winslow N, Vandegriff KD, Winslow RM TRANSLATIONAL RES 2008 149 6 333-342
30. 897016 Oxidation and haem loss kinetics of poly(ethylene glycol)-conjugated hemoglobin (MP4): Dissociation between in vitro and in vivo oxidation rates. Vandegriff KD, Malavalli A, Minn C, Jiang E, Lohman J, Young MA, Winslow RM BIOCHEM J 2006 399 3 463-471
31. 907516 Sangart, Inc. completes enrollment in second phase III study of Hemospan, a novel oxygen transport agent. Sangart Inc PRESS RELEASE 2008 May 19
32. 915381 HBOC-201 as an alternative to blood transfusion: Efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. Jahr S, Mackenzie C, Pearce LB, Pitman A, Greenburg AG J TRAUMA 2008 64 6 1484-1497
33. 925000 Predisposition to atherosclerosis in the head, heart and legs. The Framingham study. Gordon T, Kannel WB J AM MED ASSOC 1972 221 7 661-666
34. 925002 Occlusive disease of the lower extremities in patients 16 to 37 years of age. DeBakey ME, Crawford ES, Garrett E, Cooley DA, Morris GC Jr, Abbott JP Ann Surg 1964 159 6 873-890
35. 925008 Blood substitutes based on modified hemoglobin prepared by encapsulation crosslinking. Chang TMS ARTIF CELS BLOD SUBST BIOTECHNOL 1992 20 2-4 154-174
36. 925009 A clinical safety trial of stroma-free hemoglobin. Savitsky JP, Doczi J, Black J, Arnold JD CLIN PHARM THER 1978 23 1 73-80
37. 925010 Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. Hess JR, MacDonald VW, Brinkley WW J APPL PHYSIOL 1993 74 4 1769-1778
38. 925011 Efficacy of a new blood substitute based on ultrapure polymerized bovine hemoglobin. Vlahakes GJ, Lee R, Jacobs EE, Austen WG EUR J CARDIOTHORAC SURG 1989 3 4 353-354
39. 925012 Arterial blood pressure response to cell-free hemoglobin solutions and the reaction with nitric oxide. Rohlfs RJ, Bruner E, Chiu A, Gonzales A, Gonzales ML, Magde D, Magde MD, Vandegriff KD, Winslow RM J BIOL CHEM 1998 273 20 12128-12134
40. 925013 Pharmacological and physicochemical factors in the pressor effects of conjugated hemoglobin-based oxygen carriers in vivo. Smani Y, Fifre A, Labrude P, Vigneron C, Faivre B J HYPERT 2007 25 3 599-608
41. 925014 Toxicities of hemoglobin solutions: In search of in vitro and in vivo model systems. Buehler PW, Alayash AI TRANSFUSION 2004 44 10 1516-1530
42. 925017 Blood product from cattle wins approval for use in humans. Lok C NATURE 2001 410 6831 855
43. 925018 Blood substitutes based on nanobiotechnology. Chang TMS TRENDS BIOTECHNOL 2006 24 8 372-377
44. 925019 The European network of transfusion medicine societies (EuroNet-TMS): The White Book 2005. Rouger P TRANS CLIN BIOL 2005 12 2 83-92
45. 2 carriers: Status in 2005. Spahn DR, Kocian R CURR PHARM DES 2005 11 31 4099-4114
46. 2 carriers on microvascular pressure. Cabrales P, Tsai AG, Winslow RM, Intaglietta M AM J PHYSIOL - HEART CIRCULAT PHYSIOL 2005 288 5 H2146-H2153
47. 925025 The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized single-blind study. Sprung J, Kindscher JD, Wahr JA, Levy JH, Monk TG, Moritz MW, O'Hara PJ ANESTH ANALG 2002 94 4 799-808
48. 925026 The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. Gould S, Moore EE, Hoyt DB, Ness PM, Norris EJ, Carson JL, Hides GA, Freeman IH, DeWoskin R, Moss GS J AM COLL SURG 2002 195 4 445-455
49. 925027 Insights from studies of blood substitutes in trauma. Moore EE, Johnson JL, Cheng AM, Masuno T, Banerjee A SHOCK 2005 24 3 197-205
50. 925993 NCT00494949: A clinical safety increasing dose study of hemospan in orthopedic surgery patients. WWW.CLINICALTRIALS.GOV 2008 July 17
51. 926009 NCT00425334: A safety study of Hemospan in total prostatectomy patients. WWW.CLINICALTRIALS.GOV 2008 July 17
52. 926010 NCT00633659: Pilot study of Hemospan in patients with chronic critical limb ischemia. WWW.CLINICALTRIALS.GOV 2008 July 17
53. 926787 Arteriosclerosis and atherosclerosis. Brown AL, Juergens JL In: PERIPHER AL VASCULAR DISEASE Allen E (Ed) Saunders (WB) Co Ltd, London, UK 1972 57-66
54. 926789 Endovascular treatment of intermittent claudication and critical limb ischemia. Arain S, White CJ In: PERIPHERAL ARTERIAL DISEASE Shammas NW (Ed), American College of Physicians, Philadelphia, PA, USA 2008 85-113
55. 926790 Hemoglobin, oxygen carriers and perioperative organ perfusion. Kocian R, Spahn DR BEST PRACT RES CLIN ANAESTHESIOL 2008 22 1 63-80
56. 928853 Hemoglobin-based oxygen carriers and trials to substitute red blood cells. Smani Y, Labrude P, Vigneron C, Faivre B TRANSFUS CLIN BIOL 2007 14 5 464-473
57. 928988 Blood substitutes - the polyheme trials Apte SS MCGIL J MED 2008 11 1 59-65
58. 929221 Blood substitutes as pharmacotherapies in clinical practice. Jahr JS, Walker V, Manoochehri K CUR OPIN ANAESTHESIOL 2007 20 4 325-330
59. 929222 Peripheral arterial disease. Ouriel K LANCET 2001 358 9289 1257-1264
60. 929223 Management of peripheral vascular disease. Baumgartner I, Schainfeld R, Graziani L ANNU REV MED 2005 56 249-272
61. 929224 Oxygen therapeutics: Can we tame hemoglobin? Alayash AI NAT REV DRUG DISCOV 2005 3 2 152-159
62. 929225 Perfluorocarbon-based oxygen delivery. Riess JG ARTIF CELS BLOD SUBST BIOTECHNOL 2006 34 6 567-580